Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for antivascular endothelial growth factor injections in patients with wet age-related macular degeneration. "The reception to Oraya Therapy is very positive. An increasing number of patients and physicians are inquiring about this clinically proven and commercially tested therapeutic option. Importantly, these highly respected and centrally located treatment centers offer patients, their families and their physicians a valuable and much-needed option for treating wet AMD," said CEO Jim Taylor in a statement. Release